![]() ![]() Discontinue rivaroxaban in patients with active pathological bleeding. Promptly evaluate any signs or symptoms of bleeding and consider the need for blood replacement. Monitor patients for signs or symptoms of bleeding. Weigh the risk of bleeding against the risk of thrombotic events in deciding whether to initiate rivaroxaban therapy in patients at increased risk of bleeding. undergoing acute, in-hospital cancer therapy), active gastrointestinal ulcer or history of bleeding within 3 months of starting treatment, or dual antiplatelet therapy. Rivaroxaban should not be administered to acutely ill medical patients at high risk for bleeding, which includes the following conditions: history of bronchiectasis, pulmonary cavitation, or pulmonary hemorrhage, active cancer/neoplastic disease (i.e. The concomitant use of other drugs that affect hemostasis increases the risk of bleeding. Use rivaroxaban cautiously in patients with any disease state in which there is an increased risk of hemorrhage. Bleeding can occur at any site during rivaroxaban therapy. Rivaroxaban is contraindicated for use by patients with active pathological bleeding in the acute phase. Rivaroxaban increases bleeding risk and can cause serious and fatal bleeding. Bleeding, epidural anesthesia, lumbar puncture, neoplastic disease, spinal anesthesia, surgery
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |